Showing results (221-230 of 234) with videos related to
Sort By:
Pageof 24
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 12, 2000
Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Studies of Ocular Complications of AIDS Research GroupJ T Holbrook, M D Davis, L D Hubbard, et al.Journal of Clinical Neuromuscular Disease|December 17, 2008
Neurophysiologic and vascular studies in erythromelalgia: a retrospective analysisP Sandroni, M D Davis, C M Harper, et al.Journal of Medicinal Chemistry|January 17, 1997
3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonistsD J Wustrow, W J Smith, A E Corbin, et al.The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907T A Pugsley, M D Davis, H C Akunne, et al.Survey of Ophthalmology|March 1, 1995
An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study GroupA C Bird, N M Bressler, S B Bressler, et al.Archives of Ophthalmology (Chicago, Ill. : 1960)|December 1, 1994
Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trialD F Martin, D J Parks, S D Mellow, et al.Archives of Ophthalmology (Chicago, Ill. : 1960)|February 17, 2000
Swelling and loss of photoreceptors in chronic human and experimental glaucomasT M Nork, J N Ver Hoeve, G L Poulsen, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonistsD J Wustrow, T Capiris, R Rubin, et al.International Journal of Peptide and Protein Research|September 1, 1994
Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analoguesD L Heyl, A M Sefler, J X He, et al.The Journal of Pharmacology and Experimental Therapeutics|August 1, 1995
CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effectsT A Rugsley, M D Davis, H C Akunne, et al.Pageof 24